The European Commission updated its guidance on the submission of early information for joint clinical assessments (JCA) of medicinal products, following revised EMA pre-authorisation guidance. The guidance details how health technology developers should provide early information to the HTA Secretariat and access the HTA IT Platform.

The Commission also launched a JCA eligibility checker to help developers determine whether a medicinal product may fall within the scope of a JCA under the EU HTA Regulation and start preparing for the assessment at an early stage.